The Isovaleric Acidemia IVA Treatment Global Market Poised For Ascendancy With Anticipated 5.8% CAGR

June 18, 2025 07:42 PM AEST | By EIN Presswire
 The Isovaleric Acidemia IVA Treatment Global Market Poised For Ascendancy With Anticipated 5.8% CAGR
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 18, 2025 /EINPresswire.com/ -- The incredible growth trajectory of the isovaleric acidemia IVA treatment market can be ascribed to increasing awareness of rare metabolic disorders, the augmentation of newborn screening programs, surging government funding for orphan diseases, and a rising demand tied to early diagnosis and genetic counseling. In 2024, the market was valued at $0.60 billion, it is predicted to surge to $0.63 billion in 2025 marking a compound annual growth rate CAGR of 5.8%.

What Is The Projected Future Growth Of The Isovaleric Acidemia IVA Treatment Market Size?
In the forecast period, the isovaleric acidemia IVA treatment market is slated to register blistering growth and is set to expand to a staggering $0.79 billion by 2029 maintaining its CAGR at 5.8%. The momentum for growth during the predicted period can be attributed to a rise in the adoption of innovative gene therapies, increasing investments in rare disease research, numerous collaborations between biotech firms and research institutes, and improvements in personalized medicine for treating metabolic disorders. Moreover, advancements in screening methodologies for newborns, developing targeted gene editing tools, and the innovation of novel enzyme replacement formulations are some of the defining trends of this period.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24269&type=smp

What Are The Key Drivers Propelling The Growth Of The Isovaleric Acidemia IVA Treatment Market?
A crucial driver of the isotonic acidemia IVA treatment market is the escalating prevalence of metabolic disorders. Metabolic disorders disrupt normal metabolic processes, impacting how the body converts food into energy. Isovaleric acidemia treatment assists in managing metabolic disorders by grapple with the buildup of toxic substances in the body, restoring normal metabolic function, and averting complications like neurological damage. For instance, in 2022, around 25.5 million people in the U.S. were diagnosed with diabetes, accounting for 7.6% of the total population, as highlighted by the American Diabetes Association.

Sustained awareness of rare genetic disorders is anticipated to fuel the market, supported by improved diagnosis techniques and comprehensive early detection. Consequently, isovaleric acidemia treatment, which reduces the buildup of toxic metabolites and mitigates metabolic crises, becomes a vital requirement.

What Key Player Strategies Are Driving The Isovaleric Acidemia IVA Treatment Market?
Major contributors to the isovaleric acidemia IVA treatment market include Nestlé Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., and CRISPR Therapeutics AG.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/isovaleric-acidemia-iva-treatment-global-market-report

How Is The Isovaleric Acidemia IVA Treatment Market Segmented?
The isovaleric acidemia IVA treatment market can be divided into segments based on:
Segments:
1. By Type:
o Classical Isovaleric Acidemia
o Moderate Isovaleric Acidemia
o Non-classical Isovaleric Acidemia
2. By Treatment:
o Dietary Management
o Enzyme Replacement Therapy
o Gene Therapy
o Pharmacological Treatment
3. By Route of Administration:
o Oral
o Injectable

Subsegments:
1. For Classical Isovaleric Acidemia:
o Dietary Management
o Carnitine Supplementation
o Glycine Supplementation
o Emergency Management
o Gene Therapy (Investigational)
2. For Non-classical Isovaleric Acidemia:
o Observation and Preventive Care
o Mild Dietary Modifications
o Occasional Supplementation
o Genetic Counseling and Monitoring

What Are The Regional Insights In The Isovaleric Acidemia IVA Treatment Market?
In 2024, North America held the largest share of the isovaleric acidemia IVA treatment market. Asia-Pacific is projected to witness the fastest growth during the forecast period. The report includes regional analysis for Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Cardiometabolic Diseases Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Comprehensive Metabolic Panel (CMP) Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/comprehensive-metabolic-panel-cmp-testing-global-market-report

Amino Acid Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/amino-acid-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.